<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024084</url>
  </required_header>
  <id_info>
    <org_study_id>2021-009</org_study_id>
    <nct_id>NCT05024084</nct_id>
  </id_info>
  <brief_title>Desflurane and Sevoflurane Minimal Flow Anesthesia on Recovery and Anesthetic Depth</brief_title>
  <official_title>Comparison of Desflurane and Sevoflurane Minimal Flow Anesthesia on Recovery Parameters and Anesthetic Depth: a Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ufuk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ufuk University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Minimal flow anesthesia has economic and environmental advantages in addition to providing&#xD;
      earlier recovery following general anesthesia. There is a paucity of data concerning the&#xD;
      effect of minimal flow anesthesia (fresh gas flow &lt;0,5 l/min) on recovery parameters. The&#xD;
      primary objective of this study is to compare the recovery parameters of desflurane and&#xD;
      sevoflurane in minimal flow anesthesia while the secondary objective is to compare the effect&#xD;
      of these agents on anesthetic depth using bispectral index.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time until extubation</measure>
    <time_frame>Up to 10 minutes after discontinuation of the volatile anesthetic</time_frame>
    <description>Time interval between discontinuation of the volatile anesthetics and removal of the endotracheal tube</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time until eye opening</measure>
    <time_frame>Up to 20 minutes after discontinuation of the volatile anesthetic</time_frame>
    <description>Time interval between discontinuation of the volatile anesthetics and eye opening with verbal command</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time until transfer readiness</measure>
    <time_frame>Up to 45 minutes after discontinuation of the volatile anesthetic</time_frame>
    <description>Time interval between discontinuation of the volatile anesthetics and Aldrete score reaching 9 or greater</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anesthetic depth provided by the volatile anesthetic</measure>
    <time_frame>Change in Bispectral Index values at 5, 10, 15, 30, 60 and 120 minutes</time_frame>
    <description>Anesthetic depth as measured by Bispectral Index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Group Sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in this arm will be given Sevoflurane (2-3%) as volatile anesthetic throughout the duration of anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Desflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in this arm will be given Desflurane (7-8%) as volatile anesthetic throughout the duration of anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minimal flow anesthesia (fresh gas flow &lt;0.5 l/min) using Sevoflurane</intervention_name>
    <description>Sevoflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min</description>
    <arm_group_label>Group Sevoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minimal flow anesthesia (fresh gas flow &lt;0.5 l/min) using Desflurane</intervention_name>
    <description>Desflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min</description>
    <arm_group_label>Group Desflurane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages between 18 and 65&#xD;
&#xD;
          -  Patients undergoing elective surgery under general anesthesia&#xD;
&#xD;
          -  Patients with an American Society of Anesthesiologists Classification I or II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Patients with a contraindication for minimal flow anesthesia&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  History of serious systemic disease (cardiac, pulmonary, hepatic)&#xD;
&#xD;
          -  Utilization of another analgesic technique such as central or peripheral nerve blocks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baturay K Kazbek, Ass. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ufuk University Faculty of Medicine Department of Anesthesiology and Reanimation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baturay K Kazbek, Ass. Prof.</last_name>
    <phone>+903122044000</phone>
    <phone_ext>4099</phone_ext>
    <email>bkkazbek@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ufuk University Dr. Rıdvan Ege Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06520</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baturay K Kazbek, Ass. Prof.</last_name>
      <phone>+903122044000</phone>
      <phone_ext>4099</phone_ext>
      <email>bkkazbek@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Taşkın D, Gedik E, Kayhan Z. Effects of Minimal Flow Sevoflurane or Desflurane Anaesthesia on Hemodynamic Parameters, Body Temperature and Anaesthetic Consumption. Turk J Anaesthesiol Reanim. 2020 Oct;48(5):356-363. doi: 10.5152/TJAR.2020.39699. Epub 2020 May 5.</citation>
    <PMID>33103139</PMID>
  </reference>
  <reference>
    <citation>Werner JG, Castellon-Larios K, Thongrong C, Knudsen BE, Lowery DS, Antor MA, Bergese SD. Desflurane Allows for a Faster Emergence When Compared to Sevoflurane without Affecting the Baseline Cognitive Recovery Time. Front Med (Lausanne). 2015 Oct 28;2:75. doi: 10.3389/fmed.2015.00075. eCollection 2015.</citation>
    <PMID>26579522</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ufuk University</investigator_affiliation>
    <investigator_full_name>Baturay Kansu Kazbek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>general anesthesia</keyword>
  <keyword>low flow anesthesia</keyword>
  <keyword>sevoflurane</keyword>
  <keyword>desflurane</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Desflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

